Oncology Venture - Multiple programme updates
Oncology Venture (OV) continues to provide regular response data from its ongoing LiPlaCis Phase II trial in patients with metastatic breast cancer (mBC). To date, 33% of the top one-third sub-population delineated by the drug response predictor (DRP) achieved partial remission (PR) or better. The data also suggested that tightening the LiPlaCis DRP threshold may increase response rates.Oncology Venture A/S, formerly known as Medical Prognosis Institute A/S, is a Denmark-based company engaged in the development of anticancer medicines. It is primarily focused on the tool development for identification of patients with the highest probability of responding to a particular drug candidate, which increases the chance that the drug candidate is to be successful in clinical trials. The Company aims to improve the response rate of anticancer medicines whose clinical development has been suspended. After the clinical trials, the Company is to out-license or sell the drug candidates with a high response rate. The Company's main drug candidates are comprised of APO010, Irofulven and LiPlaCis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.